Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from the Benelux countries Belgium, Luxembourg and The Netherlands or involving organisations from these countries.

Total search results: 1601 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Coave Therapeutics–Fund+: investment, 202501 financing round Series A totalling €32m incl existing + co-investor Fund+ 2025-01-09
Coave Therapeutics–SEVERAL: investment, 202501 financing round Series A €32m co-led by Novo Holdings + Bpifrance InnoBio 2025-01-09
Numab–Cormorant Asset Management: investment, 202501 financing round Series C extension totalling CHF50m incl existing + co-lead investor Cormorant AM 2025-01-09
Numab–SEVERAL: investment, 202501 financing round Series C extension CHF50m bringing total Series C to CHF180m 2025-01-09
Alesta Therapeutics–Droia Ventures: investment, 202501 financing round Series A totalling €65m incl co-lead investor Droia Ventures 2025-01-08
Alesta Therapeutics–Frazier: investment, 202501 financing round Series A totalling €65m incl co-lead investor Frazier Life Sciences 2025-01-08
Alesta Therapeutics–Kendall Investor Relations: public relations, 202501 supply service existent by Kendall IR 2025-01-08
Alesta Therapeutics–Novartis: investment, 202501 financing round Series A totalling €65m incl co-investor Novartis Venture Fund 2025-01-08
Alesta Therapeutics–RTW Investments: investment, 202501 financing round Series A totalling €65m incl co-investor RTW Investments 2025-01-08
Alesta Therapeutics–SEVERAL: investment, 202501 financing round Series A €65m co-led by Frazier Life Sciences + Droia Ventures 2025-01-08
Alesta Therapeutics–SSI Strategy: investment, 202501 financing round Series A totalling €65m incl co-investor SSI Strategy 2025-01-08
Alesta Therapeutics–Thuja Capital: investment, 202501 financing round Series A totalling €65m incl existing + co-investor Thuja Capital 2025-01-08
Alesta Therapeutics–Vetter: investment, 202501 financing round Series A totalling €65m incl co-investor RV Invest 2025-01-08
Orbis Medicines–Forbion: investment, 202501 financing round Series totalling €90m incl existing + co-investor Forbion 2025-01-06
Orbis Medicines–SEVERAL: investment, 202501 financing round Series €90m led by NEA 2025-01-06
HUB Organoids–Merck (DE): investment, 202412– acquisition €na of HUB Organoids Holding BV by Merck SIGNED 2024-12-17
Formo Bio–EU (govt): credit, 202412– venture debt loan €35m from EIB 2024-12-16
Mainz Biomed–SEVERAL: investment, 202412 follow-on offering $8m with 1.37m units (1 share + 1 Class A + 1 Class B warrant) at $5.85/unit 2024-12-16
Tromp Medical–Gilde Investment: investment, 202412 investment by new investor Gilde Healthcare 2024-12-16
VectorY–Vigo Consulting: public relations, 202412 service existent by Vigo Consulting 2024-12-16
Abliva–Pharming: investment, 202412– acquisition cash tender offer SEK725m ($66.1m) at SEK 0.45/share by Pharming ANNOUNCED 2024-12-15
RhyGaze–BioGeneration Ventures: investment, 202412 financing round Series A totalling $86m incl existing + co-investor BGV 2024-12-13
RhyGaze–SEVERAL: investment, 202412 financing round Series A $86m led by GV 2024-12-13
Andera Partners–New York Life: investment, 202412– acquisition €na of 40% minority share in Andera by New York Life Investments 2024-12-12
Citryll–SEVERAL: investment, 202412 financing round Series B €85m co-led by JnJ JJDC + Forbion + Novartis Venture Fund 2024-12-09
GSK–Muna Therapeutics: drug target discovery, 202412– collab strategic alliance €33.5m upfront + milestones MiND-MAP platform for Alzheimer targets 2024-12-05
HexagonFab–Merck (DE): investment, 202412 financing round Series A totalling £6.6m of Abselion incl lead investor M Ventures 2024-12-04
HexagonFab–SEVERAL: investment, 202412 financing round Series A £6.6m of Abselion led by M Ventures 2024-12-04
miDiagnostics–Alychlo: investment, 202412 financing round Series D totalling €30m incl existing + co-investor Alychlo 2024-12-04
miDiagnostics–Pamica: investment, 202412 financing round Series D totalling €30m incl existing + co-investor Pamica 2024-12-04
miDiagnostics–SEVERAL: investment, 202412 financing round Series D €30m led by Thermo Fisher Scientific 2024-12-04
miDiagnostics–Thermo Fisher: investment, 202412 financing round Series D totalling €30m incl lead investor Thermo Fisher Scientific 2024-12-04
miDiagnostics–VMF Invest: investment, 202412 financing round Series D totalling €30m incl existing + co-investor VMF Invest 2024-12-04
Carl Roth–Bio Inx: bioinks, 202411– distribution ww of entire portfolio of bioinks of Bio Inx by Carl Roth 2024-11-27
Adcendo–SEVERAL: investment, 202411 financing round Series B $135m led by TCGX 2024-11-26
Cradle Bio–Index Ventures: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Index Ventures 2024-11-26
Cradle Bio–Institutional Venture Partners: investment, 202411 financing round Series B totalling $73m incl new + lead investor IVP 2024-11-26
Cradle Bio–Kindred Capital: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Kindred Capital 2024-11-26
Cradle Bio–SEVERAL: investment, 202411 financing round Series B $73m led by IVP 2024-11-26
Grifols–Cradle Bio: protein engineering, 202411 supply existent Grifols is user of AI-based protein engineering platform 2024-11-26
JnJ–Cradle Bio: protein engineering, 202411 supply existent JnJ Innovative Medicine is user of AI-based protein engineering platform 2024-11-26
Novo Group–Cradle Bio: protein engineering, 202411 supply existent Novo Nordisk is user of AI-based protein engineering platform 2024-11-26
Novonesis–Cradle Bio: protein engineering, 202411 supply existent Novonesis is user of AI-based protein engineering platform 2024-11-26
Biotheus–BioNTech: investment, 202411– acquisition 100% for $800m upfront mostly in cash + few ADSs plus $150m milestones 2024-11-13
Centogene–Charme Capital Partners: investment, 202411– acquisition €8.7m of sole operating subsidiary Centogene GmbH by affiliate of Charme Capital 2024-11-13
Mainz Biomed–Thermo Fisher: colorectal cancer screening test, 202411– collab developm + commercialisation assays for mRNA-based CRC screening tests 2024-11-12
Zymofix–High-Tech Gründerfonds: investment, 202411 financing round totalling €2m incl lead investor HTGF 2024-11-12
Zymofix–SEVERAL: investment, 202411 financing round €2m led by HTGF 2024-11-12
Kivu Bioscience–BioGeneration Ventures: investment, 202410 financing round Series A totalling $92m incl existing + co-investor BGV 2024-10-28
Kivu Bioscience–Gimv: investment, 202410 financing round Series A totalling $92m incl new + co-investor Gimv 2024-10-28
Kivu Bioscience–Lonza: ADC technology, 202410 existent use of GlycoConnect platform fo Synaffix by Kivu Bioscience 2024-10-28
Kivu Bioscience–Merck (DE): investment, 202410 financing round Series A totalling $92m incl existing + co-investor M Ventures 2024-10-28
Kivu Bioscience–Netherlands (govt): investment, 202410 financing round Series A totalling $92m incl existing + co-investor BOM 2024-10-28
Kivu Bioscience–SEVERAL: investment, 202410 financing round Series A $92m led by Novo Holdings 2024-10-28
Immatics–SEVERAL: investment, 202410– proposed public offering $150m 2024-10-10
Lumicks–EU (govt): credit, 202410– venture debt financing €20m from EIB to advance high-througput cell avidity platform 2024-10-10
Enara Bio–Merck (DE): investment, 202410 financing round Series B totalling $32.5m incl new + co-lead investor M Ventures 2024-10-03
Enara Bio–SEVERAL: investment, 202410 financing round Series B $32.5m co-led by new investors Pfizer Ventures + M Ventures 2024-10-03
LoQus23 Therapeutics–Forbion: investment, 202410 financing round Series A totalling £35m incl new + lead investor Forbion 2024-10-02
LoQus23 Therapeutics–SEVERAL: investment, 202410 financing round Series A £35m led by new investor Forbion 2024-10-02
LoQus23 Therapeutics–SV Health Investors: investment, 202410 financing round Series A totalling £35m incl existing + co-investor DDF 2024-10-02
Roivant–Organon: investment, 202409– acquisition of Dermavant Sciences by Organon $175m upfront + $1.025b milestones plus royalties incl product Vtama 2024-09-18
ImmunOs Therapeutics–Gimv: investment, 202409 financing round Series C totalling $11m incl existing + co-lead investor Gimv 2024-09-17
ImmunOs Therapeutics–SEVERAL: investment, 202409 financing round Series C $11m led by Gimv + Pfizer Ventures + Mission BioCapital + BioMedPartners 2024-09-17
Cell Signaling Technology–e-Blot Life Science: imaging system, 202409– distribution of Touch Imager system by Bioké in 12 European countries 2024-09-16
Abolis Biotechnologies–Icos Capital: investment, 202409 financing round totalling €35m incl investor Icos Capital 2024-09-12
Abolis Biotechnologies–SEVERAL: investment, 202409 financing round €35m with BOLD L’Oréal VC Fund + Evonik Venture Capital et al 2024-09-12
Inflammatix–SEVERAL: investment, 202409 financing round Series E $57m led by Khosla Ventures + Think.Health 2024-09-12
Inflammatix–Vesalius Biocapital: investment, 202409 financing round Series E totalling $57m incl co-investor Vesalius Biocapital 2024-09-12
Novameat–Forbion: investment, 202409 financing round Series A totalling €17.4m incl new + co-lead investor Forbion BioEconomy Fund 2024-09-12
Novameat–Praesidium: investment, 202409 financing round Series A totalling €17.4m incl existing + co-investor Praesidium 2024-09-12
Novameat–Rubio Impact Ventures: investment, 202409 financing round Series A totalling €17.4m incl existing + co-investor Rubio Impact Ventures 2024-09-12
Novameat–SEVERAL: investment, 202409 financing round Series A €17.4m led by Sofinnova Partners + Forbion BioEconomy Fund 2024-09-12
Organon–Bao Pharmaceutical: long-acting FSH, 202409– license + supply agreem for SJ02 in Mainland China $12m upfront + milestones 2024-09-12
PanTera–SEVERAL: investment, 202409 financing round Series A €93m led by EQT Life Sciences 2024-09-11
Solasta Bio–SEVERAL: investment, 202409 financing round Series A $14m led by Forbion BioEconomy Fund 2024-09-11
Formo Bio–SEVERAL: investment, 202409 financing round Series B $61m from existing + new investors 2024-09-10
eGenesis–Lux Capital: investment, 202409 financing round Series D totalling $191m incl lead investor Lux Capital 2024-09-04
eGenesis–SEVERAL: investment, 202409 financing round Series D $191m from existing + new investors led by Lux Capital 2024-09-04
Mainz Biomed–Liquid Biosciences: AI-based cancer diagnostics, 202409– collab expansion using EMERGE platform to advance PancAlert screening test 2024-09-04
Qiagen–SEVERAL: credit, 202409–2031 placement of $500m senior unsecured net share settled convertible bonds due 2031 2024-09-03
Caresyntax–SEVERAL: credit, 202408 up to $100m growth debt facility 2024-08-15
Caresyntax–SEVERAL: investment, 202408 financing round Series C extension $80m 2024-08-15
PL BioScience–Brightlands Venture Partners: investment, 202408 financing round Series A totalling €7.8m incl existing investor BVP Fund IV 2024-08-08
PL BioScience–SEVERAL: investment, 202408 financing round Series A €7.8m with new + existing investors 2024-08-08
PL BioScience–TechVision Fonds: investment, 202408 financing round Series A totalling €7.8m incl existing investor TechVision Fonds 2024-08-08
NEC–Asahi Glass: contract manufacturing, 202408– collab developm production techn + supply cancer vaccine NECVAX-NEO1 by AGC Biologics + NEC Bio Tx 2024-08-07
Confo Therapeutics–SEVERAL: investment, 202407 financing round Series B €60m led by Ackermans & van Haaren 2024-07-26
Axa–Zyme Communications: public relations, 202406 service existent for Kadans Science Partner by Zyme 2024-07-24
Draupnir Bio–ABP (NL): Investment, 202407 seed financing round totalling €12m incl existing investor Inkef Capital 2024-07-17
Draupnir Bio–Gilde Investment: Investment, 202407 seed financing round totalling €12m incl existing investor Gilde Healthcare Partners 2024-07-17
Draupnir Bio–SEVERAL: Investment, 202407 seed financing round €12m with MP Healthcare + EIFO + Gilde HP + Inkef Capital + Novo Holdings 2024-07-17
Asceneuron–EQT: investment, 202407 financing round Series C totalling $100m incl new + co-investor EQT Life Sciences - LSP Dementia Fund 2024-07-16
Asceneuron–Merck (DE): investment, 202407 financing round Series C totalling $100m incl existing + co-investor M Ventures 2024-07-16
Asceneuron–OrbiMed: investment, 202407 financing round Series C totalling $100m incl new + co-investor OrbiMed 2024-07-16
Asceneuron–SEVERAL: investment, 202407 financing round Series C $100m led by Novo Holdings 2024-07-16
Catalym–Bioqube Ventures: investment, 202407 financing round Series D totalling $150m incl new + co-lead investor Bioqube Ventures 2024-07-16
Catalym–Brandon Capital: investment, 202407 financing round Series D totalling $150m incl existing + co-investor Brandon Capital 2024-07-16
Catalym–Canaan Partners: investment, 202407 financing round Series D totalling $150m incl new + co-lead investor Canaan Partners 2024-07-16
Catalym–Forbion: investment, 202407 financing round Series D totalling $150m incl existing + co-investor Forbion Growth Opportunities Fund 2024-07-16
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  next pagenext page



Advertisement

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Events RegMed Forum 2025 HealthCapital 650x300px

» top